Wed, Jul 30, 2014, 11:40 AM EDT - U.S. Markets close in 4 hrs 20 mins

Recent

% | $
Click the to save as a favorite.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • hankmanoo hankmanoo Aug 17, 2013 10:03 PM Flag

    Recovery yield for Alpha1-antitrypsin (AAT) achieved with its PPPSTM now represents an over three fold improvement over the existing indust

    Creating the Next Generation of
    Plasma Drugs
    ProMetic’s Plasma Protein Purification System (PPPSTM) is
    extending its lead on legacy plasma manufacturing
    technologies. On Wednesday this week, it confirmed that
    the recovery yield for Alpha1-antitrypsin (AAT) achieved
    with its PPPSTM now represents an over three fold
    improvement over the existing industry average. In value
    terms, PPPSTM’s superiority across all types of plasma
    proteins represents at least a seven fold improvement
    over the industry average of $360/litre.
    This is game changer for an industry which, in many
    respects, is still a niche market focused on a narrow
    range of products/diseases and limited to the developed
    world. PPPSTM has the ability to make plasma proteins a
    mainstream industry by making it more accessible to
    emerging markets as well as meeting the demand of
    increasingly value conscious healthcare buyers in the
    developed economies.
    AAT will be the second orphan drug to be manufactured
    and commercialised at PLI’s own PPPSTM facility in Laval
    and Hematech’s future facility in Taipei, the first being a
    human plasminogen drug for the treatment of
    hypoplasminogenemia, or type I plasminogen deficiency
    (T1PD).
    The Q2/13 financial results reported yesterday confirmed
    that the company is on track to deliver substantial
    revenue growth in calendar 2013 and 2014. More
    important, it is continuing to invest in the Laval facility,
    its plasma protein pipeline and in the advancement of it
    lead therapeutic drug, PBI-4050, for fibrosis.
     Taking Plasma Global
    In 2011, three-quarters of the plasma protein market was
    dominated by just four proteins: IVIG, Albumin, Factor VIII
    and Factor, and geographically by two regions, the US and the
    EU. Not surprisingly, the global capacity is concentrated in the
    US and EU and dominated by a small number of high capacity
    commercial fractionators such CSL Behring, Baxter, Bayer and
    Octopharma.
    PLI’s strategy has attracted considerable investment fr

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AEGR
34.91+4.29(+14.02%)11:39 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.